Your response to GLP-1 may not match the iteming below
Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C: Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
This unified mechanism underpins the clinical efficacy observed across all FDA-approved GLP-1 RAs, though individual agents differ in pharmacokinetics and the relative emphasis on gastric versus central pathways
The distinction is clinically important: if you experience nausea, vomiting, or abdominal discomfort, these are recognized tirzepatide-related effects that may improve with time or dose adjustment